Delving into the Latest Updates on Schering Plough A/S with Synapse

Overview

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACS

Start Date04 Sep 2004

Sponsor / Collaborator

Schering Plough A/S

100 Clinical Results associated with Schering Plough A/S

Login to view more data

0 Patents (Medical) associated with Schering Plough A/S

Login to view more data

100 Deals associated with Schering Plough A/S

Login to view more data

100 Translational Medicine associated with Schering Plough A/S

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NGD-944 ( D4 receptor )	Schizophrenia More	Discontinued
Taltrimide	Epilepsy More	Discontinued
Nitridocade	Diagnostic agents More	Discontinued
Monoclonal antibody LYM-1-I-131(Northwest University) ( CD74 )	Non-Hodgkin Lymphoma More	Discontinued
NGD-941 ( D4 receptor )	Behavioural disorders More	Discontinued